survodutide GLP-1 glucagon
Selected indexed studies
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. (Lancet Diabetes Endocrinol, 2024) [PMID:38330987]
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (Diabetes Care, 2024) [PMID:38843460]
- Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. (Diabetologia, 2024) [PMID:38095657]
_Worker-drafted node — pending editorial review._
Connections
survodutide GLP-1 glucagon is a side effect of
Sources
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. (2026) pubmed
- Emerging pharmacotherapies for obesity: A systematic review. (2025) pubmed
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (2024) pubmed
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. (2024) pubmed
- Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. (2024) pubmed
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. (2024) pubmed
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. (2024) pubmed
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care. (2025) pubmed
- Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. (2025) pubmed
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. (2024) pubmed